SE9903995D0 - New combination - Google Patents

New combination

Info

Publication number
SE9903995D0
SE9903995D0 SE9903995A SE9903995A SE9903995D0 SE 9903995 D0 SE9903995 D0 SE 9903995D0 SE 9903995 A SE9903995 A SE 9903995A SE 9903995 A SE9903995 A SE 9903995A SE 9903995 D0 SE9903995 D0 SE 9903995D0
Authority
SE
Sweden
Prior art keywords
new combination
active ingredient
beta2
beta
kit
Prior art date
Application number
SE9903995A
Other languages
Swedish (sv)
Inventor
Jan Trofast
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9903995A priority Critical patent/SE9903995D0/en
Publication of SE9903995D0 publication Critical patent/SE9903995D0/en
Priority to CN00815363A priority patent/CN1387431A/en
Priority to KR1020027005683A priority patent/KR20020050254A/en
Priority to IL14936500A priority patent/IL149365A0/en
Priority to CA002388657A priority patent/CA2388657A1/en
Priority to BR0015172-6A priority patent/BR0015172A/en
Priority to JP2001534368A priority patent/JP2003513037A/en
Priority to PCT/SE2000/002115 priority patent/WO2001032163A1/en
Priority to AU16526/01A priority patent/AU1652601A/en
Priority to EP00975117A priority patent/EP1242065A1/en
Priority to PCT/SE2000/002116 priority patent/WO2001032166A1/en
Priority to AU13214/01A priority patent/AU1321401A/en
Priority to MXPA02004334A priority patent/MXPA02004334A/en
Priority to ZA200203178A priority patent/ZA200203178B/en
Priority to NO20022103A priority patent/NO20022103L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides a pharmaceutical composition, pharmaceutical product or kit comprising a first active ingredient which is a beta2 ( beta 2) adrenoreceptor agonist and a second active ingredient which is a leukotriene receptor antagonist, for use in the treatment of inflammatory disorders.
SE9903995A 1999-11-03 1999-11-03 New combination SE9903995D0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SE9903995A SE9903995D0 (en) 1999-11-03 1999-11-03 New combination
MXPA02004334A MXPA02004334A (en) 1999-11-03 2000-10-27 NEW COMBINATION COMPRISING A BETA 2 (bgr;)2.
JP2001534368A JP2003513037A (en) 1999-11-03 2000-10-27 Novel combination comprising β2 (β2) adreno receptor agonist and leukotriene antagonist
AU16526/01A AU1652601A (en) 1999-11-03 2000-10-27 New combination comprising a beta2-adrenoreceptor agonist and a leukotriene receptor antagonist
IL14936500A IL149365A0 (en) 1999-11-03 2000-10-27 NEW COMBINATION COMPRISING A BETA 2(β)2 ADRENO RECEPTOR AGONIST AND A LEUKOTRIENE RECEPTOR ANTAGONIST
CA002388657A CA2388657A1 (en) 1999-11-03 2000-10-27 New combination comprising a beta 2 (.beta.)2 adreno receptor agonist and a leukotriene receptor antagonist
BR0015172-6A BR0015172A (en) 1999-11-03 2000-10-27 New combination comprising a beta 2 adrenaline agonist (beta 2) and a leukotriene receptor antagonist
CN00815363A CN1387431A (en) 1999-11-03 2000-10-27 Combination comprising beta 2 adranoreceptor agonist and lenkotriene receptor antagonist
PCT/SE2000/002115 WO2001032163A1 (en) 1999-11-03 2000-10-27 NEW COMBINATION COMPRISING A BETA 2 (β)2 ADRENO RECEPTOR AGONIST AND A LENKOTRIENE RECEPTOR ANTAGONIST
KR1020027005683A KR20020050254A (en) 1999-11-03 2000-10-27 New Combination Comprising a Beta 2 (β2) Adreno Receptor Agonist and a Leukotriene Receptor Antagonist
EP00975117A EP1242065A1 (en) 1999-11-03 2000-10-27 New combination comprising a beta 2 (beta)2 adreno receptor agonist and a leukotriene receptor antagonist
PCT/SE2000/002116 WO2001032166A1 (en) 1999-11-03 2000-10-27 NEW COMBINATION COMPRISING A β2-ADRENORECEPTOR AGONIST AND A LEUKOTRIENE RECEPTOR ANTAGONIST
AU13214/01A AU1321401A (en) 1999-11-03 2000-10-27 New combination comprising a beta 2 (beta)2 adreno receptor agonist and a leukotriene receptor antagonist
ZA200203178A ZA200203178B (en) 1999-11-03 2002-04-22 New combination comprising a beta 2 (beta)2 adreno receptor agonist and a leukotriene receptor antagonist.
NO20022103A NO20022103L (en) 1999-11-03 2002-05-02 New combination including a beta 2 (<beta>) 2 andrenoreceptor agonist and leukotriene receptor antagonist

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9903995A SE9903995D0 (en) 1999-11-03 1999-11-03 New combination

Publications (1)

Publication Number Publication Date
SE9903995D0 true SE9903995D0 (en) 1999-11-03

Family

ID=20417605

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9903995A SE9903995D0 (en) 1999-11-03 1999-11-03 New combination

Country Status (13)

Country Link
EP (1) EP1242065A1 (en)
JP (1) JP2003513037A (en)
KR (1) KR20020050254A (en)
CN (1) CN1387431A (en)
AU (2) AU1321401A (en)
BR (1) BR0015172A (en)
CA (1) CA2388657A1 (en)
IL (1) IL149365A0 (en)
MX (1) MXPA02004334A (en)
NO (1) NO20022103L (en)
SE (1) SE9903995D0 (en)
WO (2) WO2001032166A1 (en)
ZA (1) ZA200203178B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
AR040962A1 (en) * 2002-08-09 2005-04-27 Novartis Ag COMPOUNDS DERIVED FROM TIAZOL 1,3-2-ONA, PHARMACEUTICAL COMPOSITION AND COMPOSITE PREPARATION PROCESS
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
WO2005097095A1 (en) * 2004-04-05 2005-10-20 Sepracor Inc. (r,r)-formoterol in combination with other pharmacological agents
ES2245612B1 (en) * 2004-06-29 2007-08-16 Universidad De Barcelona NEW THERAPEUTIC USE OF FORMOTEROL.
SI1863476T1 (en) * 2005-03-16 2016-05-31 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
BR112013028959A2 (en) * 2011-06-06 2016-08-30 Chiesi Farma Spa compound, process for preparing a compound, compounding a compound, pharmaceutical composition, use of a compound, device and kit
CN104822659A (en) * 2012-12-05 2015-08-05 奇斯药制品公司 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors
JP5846185B2 (en) 2013-11-21 2016-01-20 大日本印刷株式会社 Through electrode substrate and semiconductor device using the through electrode substrate
PT109030B (en) * 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. PREPARATION OF ZAFIRLUCAST INHALABLE PARTICULES

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604752D0 (en) * 1996-12-20 1996-12-20 Astra Ab Formulation and use
JP2001514660A (en) * 1997-03-13 2001-09-11 メルク エンド カンパニー インコーポレーテッド Quinoline leukotriene antagonist
SE9704644D0 (en) * 1997-12-12 1997-12-12 Astra Ab New use

Also Published As

Publication number Publication date
ZA200203178B (en) 2003-07-22
WO2001032163A1 (en) 2001-05-10
CN1387431A (en) 2002-12-25
CA2388657A1 (en) 2001-05-10
BR0015172A (en) 2002-06-18
IL149365A0 (en) 2002-11-10
EP1242065A1 (en) 2002-09-25
KR20020050254A (en) 2002-06-26
NO20022103D0 (en) 2002-05-02
AU1321401A (en) 2001-05-14
NO20022103L (en) 2002-05-02
JP2003513037A (en) 2003-04-08
AU1652601A (en) 2001-05-14
WO2001032166A1 (en) 2001-05-10
MXPA02004334A (en) 2002-11-07

Similar Documents

Publication Publication Date Title
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
DK0668863T3 (en) Quinuclidine derivative as substance P antagonist
HUP0203586A2 (en) The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist
DK1135153T3 (en) Uses of EPH receptor antagonists and agonists for the treatment of vascular disorders
MXPA03000548A (en) New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation.
AR025883A1 (en) USE OF ANTAGONISTS OF THE CENTRAL CANNABINOID RECEPTORS FOR THE PREPARATION OF MEDICINES
HUP0203590A2 (en) Remedies for diseases in association with decrease in bone mass
MXPA06002722A (en) A pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti inflammatory drug.
SE9903995D0 (en) New combination
ATE260650T1 (en) ORAL DOSAGE FORMS FOR ADMINISTRATION OF A FIXED COMBINATION OF TRAMADOL AND DICLOFENAC
NO20020574L (en) Substituted 1,5-dihydropyrrol-2-one derivatives that act as NMDA receptor antagonists for the treatment of the pain state
BG105256A (en) Muscarinic agonists and antagonists
DK1104289T3 (en) New oral formulations for 5-HT 4 agonists or antagonists
AU4179399A (en) Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
SE9902935D0 (en) Pharmaceutical compositions
EE05211B1 (en) Use of saredutant and its pharmaceutically acceptable salts in the preparation of medicaments useful for the treatment or prevention of mood disorders, adaptive disorders, or mixed depressive disorders.
HUP0002346A1 (en) Pharmaceutical composition for the treatment of mental illness in mammals
EE200100520A (en) N- (2-phenyl-4-aminobutyl) -1-naphthamides as neurokinin-1 receptor antagonists
SE0300445D0 (en) New combination
BG106548A (en) Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog
EE200100689A (en) Use of IL6RIL6 Chimera for the preparation of a medicament for the treatment of neurological diseases, and pharmaceutical composition
SE0001916D0 (en) Novel formulation
BR9812531A (en) Combination of components, pharmaceutical preparation, production thereof, and use of the combination or pharmaceutical preparation
SE9902936D0 (en) Pharmaceutical compositions
AU2002212441A1 (en) Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain